Continuing Burden of Refractory Epilepsy

Annals of Pharmacotherapy - Tập 55 Số 3 - Trang 406-408 - 2021
Marnie T. Janson1, Jacquelyn Bainbridge2
1Veterans Affairs Eastern Colorado Health Care System, Aurora, CO, USA
2University of Colorado, Aurora, CO, USA

Tóm tắt

Epilepsy is one of the most common neurological diseases, and uncontrolled seizures remain a significant problem for one-third of patients with epilepsy on drug therapy. Ongoing seizures affect the morbidity and mortality of patients with epilepsy. Premature death is up to 3 times higher in those with epilepsy than in the general population. Quality of life is affected by refractory epilepsy with physical, social, and psychological consequences. Patients may be stigmatized by society, institutions, and their own shame surrounding seizures. Questions remain on how to treat refractory epilepsy, also called drug-resistant, pharmacoresistant, or intractable epilepsy. Cenobamate, a novel antiseizure medication, may provide additional benefit for refractory epilepsy treatment.

Từ khóa


Tài liệu tham khảo

10.1111/j.1468-1331.2006.01215.x

10.1056/NEJM200002033420503

10.1111/j.1528-1167.2009.02397.x

10.2165/00023210-199810030-00002

10.1016/j.yebeh.2007.11.013

10.1016/S1474-4422(08)70202-3

10.1007/s11910-014-0502-4

10.1212/WNL.0000000000003685

World Health Organization, 2019, Epilepsy: A Public Health Imperative

10.1016/S1474-4422(17)30299-5

10.1016/j.jfma.2015.07.015

10.1097/MLR.0b013e31826c8613.

10.1016/0920-1211(96)00017-4

10.1111/j.1528-1157.1996.tb00006.x

10.1212/WNL.0b013e31827b1ae0

10.1111/epi.13769

Global Burden of Disease Collaborative Network, 2017, Global Burden of Disease Study 2016 (GBD 2016) Results

10.1111/1467-9566.ep11346455

10.1053/seiz.2002.0711

10.1053/seiz.2000.0442

10.1016/S1474-4422(19)30399-0

10.1136/bmj.g254

10.1001/jamaneurol.2017.3949

10.1016/j.seizure.2011.01.004

Thông tin
Thông tin xuất bản

Annals of Pharmacotherapy

Tập 55 Số 3

406-408

Thông tin tác giả